Trials / Completed
CompletedNCT04498910
A Study of LY3451838 in Participants With Migraine
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY3451838 in Adults With Treatment-Resistant Migraine
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this study is to see if the study drug LY3451838 is safe and effective in participants who have migraine that have not responded to other preventive treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3451838 | Administered IV |
| DRUG | Placebo | Administered IV |
Timeline
- Start date
- 2020-11-16
- Primary completion
- 2022-11-09
- Completion
- 2022-11-09
- First posted
- 2020-08-05
- Last updated
- 2023-11-28
- Results posted
- 2023-11-28
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04498910. Inclusion in this directory is not an endorsement.